Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05112536
Recruitment Status : Recruiting
First Posted : November 9, 2021
Last Update Posted : June 9, 2022
Sponsor:
Information provided by (Responsible Party):
G1 Therapeutics, Inc.

Brief Summary:

The purpose of this study is to evaluate the mechanism of action, as well as the safety and efficacy of trilaciclib in combination with standard of care treatment in the neoadjuvant setting of early-stage triple negative breast cancer (TNBC).

This study will have four phases: 1) Screening Phase, 2) Trilaciclib Lead-In Phase, 3) Treatment Phase, and 4) Surgery and Follow-Up Phase. After a screening phase of up to 21 day, each participant will receive trilaciclib single-dose monotherapy during the lead-in phase, followed by a tumor biopsy. During the treatment phase, each participant will receive trilaciclib with standard of care chemotherapy. Immunotherapy may be included during the treatment phase, per standard of care. 3-5 weeks following conclusion of the treatment phase, each participant will undergo definitive surgery. A 30-day Safety Follow-up Visit will occur 30 days after the last dose of trilaciclib and an End of Study Visit will occur within 14 days after definitive surgery.


Condition or disease Intervention/treatment Phase
Triple Negative Breast Cancer Breast Cancer Drug: Trilaciclib Drug: Cylophosphamide Drug: Doxorubicin Drug: Paclitaxel Drug: Carboplatin (Investigator discretion) Biological: Pembrolizumab (Investigator discretion) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
Actual Study Start Date : November 19, 2021
Estimated Primary Completion Date : August 20, 2022
Estimated Study Completion Date : February 24, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Trilaciclib

Arm Intervention/treatment
Experimental: Trilaciclib plus chemotherapy

Trilaciclib lead-in, followed by trilaciclib plus anthracycline/cyclophosphamide, then trilaciclib plus taxane chemotherapy:

  • Lead-in trilaciclib (240mg/m2) single dose monotherapy
  • Trilaciclib (240mg/m2) + doxorubicin (60 mg/m2) + cyclophosphamide (600 mg/m2) + pembrolizumab (per Investigator discretion; 400mg)
  • Trilaciclib (240mg/m2) + paclitaxel (80 mg/m2) + carboplatin (per Investigator discretion; AUC 1.5)
Drug: Trilaciclib
Trilaciclib is administered IV as monotherapy during the lead-in phase and administered prior to chemotherapy on each day chemotherapy is administered during the treatment phase.
Other Names:
  • COSELA®
  • G1T28

Drug: Cylophosphamide
Cyclophosphamide administered IV every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Other Name: CYTOXAN®

Drug: Doxorubicin
Doxorubicin administered as an IV bolus every 2 weeks for the first 4 cycles (1-4), each cycle 2 weeks in length.
Other Name: ADRIAMYCIN®

Drug: Paclitaxel
Paclitaxel administered weekly for the last 12 cycles (cycles 5-16), each cycle 1 week in length.
Other Name: TAXOL®

Drug: Carboplatin (Investigator discretion)
Carboplatin, if given, is administered IV weekly at the start of paclitaxel administration, for the last 12 cycles (cycles 5-16).
Other Name: PARAPLATIN®

Biological: Pembrolizumab (Investigator discretion)
Pembrolizumab, if given, is administered IV every 6 weeks throughout the treatment phase (cycles 1, 4, 9, 15).
Other Name: KEYTRUDA®




Primary Outcome Measures :
  1. Immune-based mechanism of action [ Time Frame: Up to 8 days ]
    Evaluated 7 days after a single-dose of trilaciclib, measured by the change in CD8 T cells/regulatory T cells (Treg) ratio in tumor tissue.


Secondary Outcome Measures :
  1. Pathologic Complete Response (pCR) rate [ Time Frame: Up to 26 weeks ]
    Rate of pCR using the definition of ypT0/Tis ypN0 (i.e., no invasive residual tumor in breast or nodes; noninvasive breast residuals allowed) as assessed by the local pathologist.

  2. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) [ Time Frame: Up to 28 weeks ]
    Safety/tolerability as per CTCAE version 5.0


Other Outcome Measures:
  1. Intratumoral immune profile characterization following trilaciclib [ Time Frame: Up to 26 weeks ]
    Characterization of molecular and immune changes based on CD8+ T cell and Treg infiltration, quantified by RNA profiling of tumor tissue before study treatment, during study treatment, and at definitive surgery.

  2. Kinetics of the immune response in peripheral blood [ Time Frame: Up to 26 weeks ]
    Longitudinal immune changes in peripheral blood, measured by frequency of immune subsets and profiling of activation, maturation, and exhaustion status.

  3. Kinetics of T cell function and polyfunctionality [ Time Frame: Up to 26 weeks ]
    Ex-vivo measurement of cytokine production to determine T cell function and polyfunctionality.

  4. Molecular biomarkers for clinical responsiveness [ Time Frame: Up to 26 weeks ]
    pCR in patients by gene signatures determined in the tumor at baseline.

  5. CDK4/6 dependence for clinical responsiveness [ Time Frame: Up to 26 weeks ]
    pCR in patients by subgroups according to CDK4/6 dependence signatures.

  6. PD-L1 status and clinical responsiveness [ Time Frame: Up to 26 weeks ]
    pCR in patients by subgroups according to PD-L1 status, as measured by IHC.

  7. Immune response and clinical responsiveness [ Time Frame: Up to 26 weeks ]
    pCR in patients by frequency of immune subsets, immunological markers, and cytokines.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Suitability of therapy and patient intends to undergo curative surgery
  • Documented diagnosis of estrogen receptor (ER)-negative and progesterone receptor (PR)-negative tumor
  • Primary tumor ≥ 2 cm with any nodal status
  • Provide archival tissue for the baseline tissue sample
  • ECOG performance status of 0 or 1
  • Demonstrates adequate organ function
  • Research tumor biopsies including at least one on-treatment biopsy (and additional biopsy at baseline, if required)
  • Participants of child bearing potential must be willing to use 2 forms of contraception during the study and for 6 months following study treatment

Exclusion Criteria:

  • Prior systemic therapies or radiation for current breast cancer
  • History of invasive malignancy ≤3 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • History of breast cancer including ipsilateral ductal carcinoma in situ (DCIS) treated with radiotherapy at any time
  • Previous exposure to doxorubicin of more than 200 mg/m2 (as lifetime exposure to doxorubicin is not to exceed 450 mg/m2)
  • For patients who will receive pembrolizumab:

    • History of active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy is not considered a form of systemic treatment
    • Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs
  • History of (non-infectious) pneumonitis that required steroids or current pneumonitis
  • Known history of active tuberculosis (Bacillus Tuberculosis)
  • History of severe hepatic impairment
  • Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure (Class II-IV as defined by the New York Heart Association [NYHA] functional classification system)
  • Known history of stroke, cerebrovascular accident, severe/unstable angina, myocardial infarction, or coronary angioplasty/stenting/bypass grafting within 6 months prior to enrollment
  • Known serious active infection (e.g., human immunodeficiency virus [HIV], hepatitis B or C, tuberculosis).
  • Women who are pregnant or breastfeeding
  • Participation in other studies involving active treatment with investigational drug(s)
  • Prior hematopoietic stem cell or bone marrow transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05112536


Contacts
Layout table for location contacts
Contact: G1 Therapeutics, Inc. Clinical Contact 919-213-9835 clinicalinfo@g1therapeutics.com
Contact: G1 Therapeutics, Inc. Clinical Contact Study Director

Locations
Layout table for location information
United States, California
Providence Medical Foundation Recruiting
Fullerton, California, United States, 92835
Contact: Blanca Sanchez       Blanca.sanchez@stjoe.org   
Contact: Teresa Olea       Teresa.Olea@stjoe.org   
Principal Investigator: William Lawler, MD         
Cancer and Blood Specialty Clinic Recruiting
Los Alamitos, California, United States, 90720
Contact: Mimi Washington       miwashington@mednet.ucla.edu   
Principal Investigator: Vu Phan, MD         
UCLA Department of Medicine - Hematology/Oncology Recruiting
Santa Monica, California, United States, 90404
Contact: Monica Rocha       MPRocha@mednet.ucla.edu   
Contact: Hiromi Yagi       HYagi@mednet.ucla.edu   
Principal Investigator: Sara Hurvitz, MD         
PIH Health Recruiting
Whittier, California, United States, 90602
Contact: Gayle Madden-Mathes, RN    562-698-0811 ext 13488    Gayle.MaddenMathes@pihhealth.org   
Contact: Rosie Drulias, RN    562-698-0811 ext 12930    Rosie.Drulias@pihhealth.org   
Principal Investigator: Lisa Wang, MD         
United States, Florida
Orlando Health Cancer Institute Recruiting
Orlando, Florida, United States, 32806
Contact: Jennifer Durand       Jennifer.Durand@orlandohealth.com   
Contact: Janice Porter       Janice.Porter@orlandohealth.com   
Principal Investigator: Regan Rostorfer, MD         
United States, Nebraska
Nebraska Hematology-Oncology, P.C. Recruiting
Lincoln, Nebraska, United States, 68506
Contact: Vienna Lionberger       vlionberger@yourcancercare.com   
Contact: Kent Disney       kdisney@yourcancercare.com   
Principal Investigator: Kailash Mosalpuria, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Michelle Parks       Michelle.parks@duke.edu   
Principal Investigator: Jeremy Force, DO         
United States, Texas
Texas Oncology - Austin Central Recruiting
Austin, Texas, United States, 78731
Contact: Michelle L. Owens       michelle.owens@usoncology.com   
Principal Investigator: Debra Patt, MD         
Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting
Dallas, Texas, United States, 75246
Contact: Jonathan B. Huntzinger       jonathan.huntzinger@usoncology.com   
Principal Investigator: Joyce A. O'Shaughnessy, MD         
United States, Virginia
Virginia Oncology Associates Recruiting
Norfolk, Virginia, United States, 23502
Contact: Angel Kidd       angel.kidd@usoncology.com   
Principal Investigator: Michael A. Danso, MD         
Sponsors and Collaborators
G1 Therapeutics, Inc.
Layout table for additonal information
Responsible Party: G1 Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT05112536    
Other Study ID Numbers: G1T28-212
First Posted: November 9, 2021    Key Record Dates
Last Update Posted: June 9, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by G1 Therapeutics, Inc.:
Breast Cancer
Triple Negative Breast Cancer
CDK4/6 Inhibitor
trilaciclib dihydrochloride
Cosela
Immuno-oncology
Solid tumor
Chemotherapy-induced myelosuppression
Myeloprotective
Cyclin-dependent kinase 4/6 inhibitor
Neoadjuvant
HER2-negative
TNBC
Breast cancer surgery
Trilaciclib
Myeloprotection
pembrolizumab
carboplatin
doxorubicin
cyclophosphamide
Dose-dense anthracycline/cyclophosphamide
paclitaxel
Chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Carboplatin
Doxorubicin
Pembrolizumab
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Immunological